Erenumab (Aimovig®) is indicated for the treatment of chronic and episodic migraine in adults who have at least 4 migraine days per month when initiating treatment with erenumab.
|NCPE Assessment Process||Complete|
|Rapid review received||19/07/2018|
|Rapid review completed||15/08/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||28/08/2018|
|Pre-submission consultation with Applicant||24/09/2018|
|Submission received from Applicant||22/01/2019|
|Preliminary review sent to Applicant||01/04/2019|
|NCPE assessment re-commenced||01/05/2019|
|Factual accuracy sent to Applicant||31/07/2019|
|NCPE assessment re-commenced||06/08/2019|
|NCPE assessment completed||30/09/2019|
|NCPE assessment outcome||Chronic Migraine: The NCPE recommends that erenumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*
Episodic Migraine: The NCPE recommends that erenumab not be considered for reimbursement.*
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.